v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue:    
Contract research revenue $ 158,333 $ 89,812
Costs and Expenses:    
Research and development 14,358,918 11,234,548
General and administrative 10,005,967 7,776,300
Total costs and expenses 24,364,885 19,010,848
Loss from operations (24,206,552) (18,921,036)
Sale of New Jersey net operating loss 1,073,289 1,007,082
Other income, net 686,425 541,303
Net loss (22,446,838) (17,372,651)
Preferred stock series A accumulated dividends (338,613)
Preferred stock series B accumulated dividends (793,442) (585,547)
Net loss attributable to common shareholders $ (23,240,280) $ (18,296,811)
Net loss attributable to common shareholders per share - basic and diluted $ (0.12) $ (0.13)
Weighted average common shares outstanding:    
Basic and diluted 196,894,628 145,195,196
Other comprehensive income/(loss), net of tax    
Net unrealized gain/(loss) on securities available-for-sale $ 237,537 $ (880)
Reclassification of realized gain on securities available-for-sale to net loss (8,485)
Other comprehensive income/(loss), net of tax 229,052 (880)
Comprehensive loss attributable to shareholders $ (22,217,786) $ (17,373,531)

Source